The provided text, originating from the Food and Drug Administration (FDA), serves as a crucial public health warning regarding counterfeit Ozempic (semaglutide) injections found within the U.S. drug supply chain. It details multiple instances where fake versions of the medication were identified and seized, highlighting specific lot and serial numbers to help consumers, pharmacies, and healthcare professionals identify these fraudulent products. The FDA emphasizes the unknown identity, quality, and safety of these counterfeits, noting that some seized products contained counterfeit needles, posing an increased risk of infection. The agency advises obtaining authentic Ozempic only through authorized distributors and licensed pharmacies, urging prompt reporting of any suspicious products or adverse events to the FDA or Novo Nordisk.
Audio Overview (Google NotebookLM)
(6 minutes 21 seconds)
